Former Bayer Senior Executive Joins Sirona Biochem Advisory Board
June 20 2022 - 3:00AM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF)
(“
Sirona”) is pleased to announce that Dr.
Wolfgang Bieber will join Sirona Biochem’s Advisory Board and act
as a consultant to the Board of Directors with immediate effect.
Dr. Wolfgang Bieber brings to Sirona Biochem 30
years of experience from his career at BAYER AG, a global
pharmaceutical and agrochemical company with sales of US$52 billion
and more than 100,000 employees. He headed Technical Operations of
biological products in the US and the agrochemical production
worldwide as Senior VP (direct expense US$300 million, capital
expense US$200 million, direct head count 1,250). Among the
biological products, Kogenate®, one of the largest recombinant
proteins manufactured worldwide, reached annual sales of US$1
billion. Dr. Bieber was also strongly involved in M&A
activities of BAYER AG.
Dr. Bieber will provide active and significant
support in the following areas:
- Connecting to
chemical manufactures in Europe.
- Assisting with
the conclusion of a partnership of Sirona Biochem’s animal health
project.
- Organizational
development of TFChem to accelerate pipeline development.
- Structuring
Sirona Biochem for sustainable growth.
- Attracting
Institutional Investors for Sirona Biochem.
“We are very pleased to have convinced Dr.
Wolfgang Bieber, a manager with many years of experience and a very
good network, to join Sirona Biochem. The company has entered a new
phase and, in addition to further operational development, now
needs in particular more seniority with industry experience to lead
projects to market significantly faster,” said Dr. Howard Verrico,
CEO of Sirona Biochem.
"I am very much looking forward to the new tasks
and will contribute my entire experience and network to bring
Sirona Biochem as well as TFChem forward structurally and to lead
the company to further maturity. Sirona's platform technology is
unique and the potential is immense. In a way, it is a diamond in
the rough that I will help to sharpen," comments Dr. Wolfgang
Bieber.
As recently announced, Sirona Biochem is
currently implementing various changes to accelerate growth and
pipeline development following the concluded global and exclusive
license agreement with AbbVie for the library of our
industry-disrupting skincare compounds, including the breakthrough
TFC-1067.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press
release, please contact:
Investor Enquiries:Jonathan WilliamsManaging
DirectorMomentum PRPhone: 1.450.332.6939Email:
jwilliams@momentumpr.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem’s forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem’s business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Aug 2023 to Aug 2024